Table 3 Clinical characteristics of patients with cTnT peak occurrence within 24 h after operation vs. cTnT peak occurrence more than 24 h after operation
Variables | Group I (n = 481) | Group II (n = 83) | P |
|---|---|---|---|
Male sex (n, %) | 380 (79.0) | 63 (75.9) | 0.525 |
Age (y) | 64.77 ± 8.22 | 68.41 ± 7.39 | < 0.001 |
Weight (kg) | 7.035 ± 10.53 | 68.30 ± 9.39 | 0.097 |
Height (cm) | 166.73 ± 6.70 | 167.29 ± 7.13 | 0.487 |
BMI (kg/m2) | 25.27 ± 3.26 | 24.35 ± 2.58 | 0.005 |
BSA (m2) | 1.76 ± 0.16 | 1.74 ± 0.15 | 0.231 |
Types of CAD | 0.643 | ||
Unstable angina pectoris (n, %) | 284 (59.0) | 48 (57.8) | |
Acute myocardial infarction (n, %) | 66 (13.7) | 9 (10.8) | |
Stable angina pectoris (n, %) | 131 (27.2) | 26 (31.3) | |
Diabetes mellitus (n, %) | 164 (34.1) | 37 (44.6) | 0.066 |
Hypertension (n, %) | 346 (71.9) | 67 (80.7) | 0.095 |
Cerebrovascular disease | 0.301 | ||
Stroke (n, %) | 18 (3.7) | 4 (4.8) | |
Lacunar infarction (n, %) | 115 (23.9) | 26 (31.3) | |
Peripheral vascular disease (n, %) | 10 (2.1) | 3 (3.6) | 0.642 |
Preoperative atrial fibrillation (n, %) | 14 (2.9) | 1 (1.2) | 0.601 |
Pulmonary hypertension (n, %) | 8 (1.7) | 4 (4.8) | 0.153 |
Serum creatinine (μmol/l) | 80.93 ± 20.31 | 91.66 ± 40.35 | 0.020 |
Ccr (ml/min/1.73 m2) | 82.18 ± 25.17 | 69.36 ± 21.67 | < 0.001 |
Renal failure (n, %) | 2 (0.4) | 2 (2.4) | 0.197 |
LVEF (%) | 0.878 | ||
LVEF ≥ 45% (n, %) | 468 (97.3) | 81 (97.6) | |
LVEF < 45% (n, %) | 13 (2.7) | 2 (2.4) | |
Triple vessel disease (n, %) | 426 (88.6) | 79 (95.2) | 0.069 |
COPD (n, %) | 7 (1.5) | 2 (2.4) | 0.868 |
Previous PCI (n, %) | 2 (0.4) | 0 (0.0) | 1.000 |
NYHA | 0.912 | ||
I (n, %) | 26 (5.4) | 4 (4.8) | |
II (n, %) | 356 (74.0) | 59 (71.1) | |
III (n, %) | 94 (19.5) | 19 (22.9) | |
IV (n, %) | 5 (1.0) | 1 (1.2) | |
EuroSCORE II | 1.72 ± 0.91 | 2.22 ± 1.12 | < 0.001 |
Operating time (min) | 266.19 ± 61.80 | 278.20 ± 75.37 | 0.115 |
Number of bypass grafts (n) | 3.67 ± 1.09 | 3.87 ± 1.02 | 0.119 |
Number of arterial grafts (n) | 1.45 ± 0.86 | 1.24 ± 0.77 | 0.028 |
Number of venous grafts (n) | 2.21 ± 1.12 | 2.67 ± 1.03 | < 0.001 |
Total arterial grafting (n, %) | 40 (8.3) | 2 (2.4) | 0.058 |
Total venous grafting (n, %) | 26 (5.4) | 9 (10.8) | 0.058 |
Peak of CK-MB (mg/l) | 19.70 (14.00, 29.05) | 32.90 (21.00, 61.00) | < 0.001 |
Peak of cTnT (mg/l) | 0.13 (0.10, 0.26) | 0.43 (0.25, 0.81) | < 0.001 |
CK-MB peak occurrence within 24 h (n, %) | 327 (68.0) | 55 (66.3) | 0.757 |
CK-MB peak value > 32.00 mg/l (n, %) | 97 (20.1) | 42 (50.6) | < 0.001 |
Follow-up time (month) | 77.10 (61.00, 94.20) | 69.10 (34.80, 86.60) | 0.001 |
Mid-term mortality (n, %) | 38 (7.9) | 22 (26.5) | < 0.001 |